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Background: Although rectal indomethacin (100mg) is effective in reducing the 
frequency and severity of post-endoscopic retrograde cholangiopancreatography 
(ERCP) pancreatitis in high-risk patients, the optimal dose is unknown and pancreatitis 
rates remain high despite its use. The aim of this study was to compare the efficacy of 
two dose regimens of rectal indomethacin on the frequency and severity of post-ERCP 
pancreatitis in high-risk patients. 
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Methods: Eligible patients were those at high-risk for the development of post-ERCP 
pancreatitis, enrolled at six tertiary centers in a randomized double-blinded comparative 
effectiveness trial. Patients, study personnel, and treating physicians were blinded to 
study group assignment. The randomization schedule, stratified according to study 
center but without other restrictions, was computer-generated by an investigator 
uninvolved in the clinical care of any subjects, distributed to the other sites, and kept by 
personnel not directly involved with the study. This same personnel was responsible for 
packaging the drug and placebo in opaque envelopes. The primary endpoint was the 
development of post-ERCP pancreatitis. Analyses were conducted by intention-to-treat 
principle. The trial was registered with Clinicaltrials.gov (https://www.clinicaltrials.gov/): 
NCT01912716, and ended with complete enrollment.  
 
Findings: 1037 eligible patients were randomized between 7/9/13-3/22/18. Pancreatitis 
occurred in 141 patients (13.6%), with no significant difference between the two groups 
(100mg vs 200mg) (76/515, 14.8% vs 65/522, 12.5%, P=0.32). There were 19 adverse 
events that were potentially attributable to the study drug. Clinically significant bleeding 
occurred in 14 of the 1037 patients (1.4%), 6/515 (1.2%) in the standard-dose group 
and 8/522 (1.5%) in the high-dose group (P = 0.79). Three patients developed acute 
kidney injury developed, all in the high-dose group (3/522, 0.6%). A non-ST elevation 
myocardial infarction occurred in the standard-dose group 2 days after ERCP. A 
transient ischemic attack occurred in the high-dose group 5 days after ERCP. All 19 
adverse events, in addition to the 141 patients who developed post-ERCP pancreatitis, 
5 
 
were considered to be serious adverse events as all required hospitalization. There 
were no allergic reactions or deaths at the 30-day follow-up. 
There was no difference between the two groups regarding incidence of bleeding or 
renal failure. No allergic reactions or deaths occurred. 
Interpretation: Dose escalation to 200mg of rectal indomethacin does not confer any 
advantage over the standard 100mg regimen, with pancreatitis rates remaining high in 
high-risk patients. Current practice patterns should continue unchanged. Further 
research needs to consider the pharmacokinetics of NSAIDs to determine the optimal 
timing of their administration in prevention of post-ERCP pancreatitis.  
Funding: This work was supported by a Clinical Research Award obtained from the 







Pancreatitis is the most frequent and potentially devastating complication of endoscopic 
retrograde cholangiopancreatography (ERCP), accounting for substantial morbidity, 
occasional mortality, and increased health care costs.1-3 Multiple pharmacologic agents 
have been evaluated in the prevention of post-ERCP pancreatitis with limited success.4 
Recently, rectal non-steroidal anti-inflammatory drugs – either indomethacin or 
diclofenac at a dose of 100mg in the peri-procedural period – have been adopted into 
widespread clinical use on the basis of high-quality randomized trials consistently 
showing an approximately 50% risk reduction in high-risk patients. The benefit in 
average–risk patients, however, remains a source of debate.5-20 Despite this advance, 
the rate of post-ERCP pancreatitis remains at or above 10% in high-risk cases despite 
pharmacoprevention and the placement of a prophylactic pancreatic stent – the only 
mechanical intervention to reduce risk.  
   
When used as an analgesic or anti-inflammatory agent in the management of patients 
with arthritis, the accepted maximal daily dose of indomethacin is 200mg per day, in 
divided doses (product insert, Merck & Co., Kenilworth, NJ). This higher dose of 
indomethacin, which should lead to a higher peak serum concentration, might further 
lower post-ERCP pancreatitis rates. In addition, since the half-life of indomethacin is 
approximately 4.5 hours, a second dose of the drug might lead to a more sustained 
impact on the inflammatory cascade. We hypothesized that both of these dose 
modifications are important in pancreatitis prevention, and that a regimen consisting of a 
higher initial dose followed by a second dose (i.e. dose escalation) would be superior to 
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the existing standard. Therefore, we conducted a randomized, double-blind trial 
comparing modified and standard dose regimens of rectal indomethacin for preventing 
post-ERCP pancreatitis in high-risk patients. 
 
Methods: 
Study design and participants 
We enrolled patients at six tertiary medical centers in the United States in a randomized 
double-blinded comparative effectiveness trial of two dosing regimens of rectal 
indomethacin for preventing post-ERCP pancreatitis in high-risk cases. Approval was 
obtained from the human studies review committee at each participating institution. 
Selected subjects who did not meet any exclusion criteria were consented for the trial 
by a clinical research coordinator or one of the investigators, with this consent process 
occurring prior to ERCP in outpatient clinic or the procedure preparation area. At this 
time, the objectives of the study as well as the risks and benefits of enrolling were 
explained in detail to potential subjects. Consent from a legal authorized representative 
was not allowed per study protocol. Patient recruitment was not consecutive as certain 
factors beyond coordinator or investigator control limited this approach (eg. procedure 
performed too late in the day to allow for administration of the 4-hour drug or placebo, 
inability to verify creatinine or lipase level). The study was granted an exemption by the 
Food and Drug Administration for an Investigational New Drug application. An 
independent data and safety monitoring board (DSMB) reviewed blinded subject data 
biannually and conducted the a priori scheduled interim analyses. The study protocol is 
available online (see appendix p1-10).  
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The eligibility criteria were intended to select a group of patients at high risk 
(approximately 10%) for post-ERCP pancreatitis. These criteria were based on patient 
and procedure-related risk factors that have been previously shown to independently 
predict pancreatitis.21 Patients were eligible if they met one or more of the following 
major criteria: clinical suspicion of sphincter of Oddi dysfunction (defined as chronic 
abdominal pain or suspected biliary or pancreatic origin, accompanied by elevated 
serum liver tests or pancreatic enzymes and/or bile or pancreatic duct dilation on 
abdominal imaging), a history of post-ERCP pancreatitis, pancreatic sphincterotomy, 
precut (access) sphincterotomy, more than eight cannulation attempts (as determined 
by the endoscopist), pneumatic dilation of an intact biliary sphincter, or papillectomy. 
Patients were also eligible if they met two or more of the following minor criteria: age 
less than 50 years and female sex, a history of recurrent pancreatitis (≥2 episodes), 
three or more contrast injections into the pancreatic duct with at least one injection to 
the tail of the pancreas, pancreatic acinarization, or pancreatic duct brush cytology. 
Patients were excluded from study participation if they met one or more of the following 
criteria: unwillingness or inability to consent for the study, age < 18 years (no upper age 
limit was exclusionary), i ntrauterine pregnancy, b reastfeeding mother, standard 
contraindications to ERCP (eg. uncontrolled coagulopathy or hemodynamic instability), 
a l l e r g y / hypersensitivity to aspirin or NSAIDs, received NSAIDS in prior 7 days 
(aspirin 325 mg or less OK), renal insufficiency (serum creatinine > 1.4 mg/dL), active or 
recent (within 4 weeks) gastrointestinal hemorrhage, acute pancreatitis (lipase peak > 
3x upper limit of normal) within 72 hours, known chronic calcific pancreatitis, pancreatic 
head mass, procedure performed on major papilla/ventral pancreatic duct in a patient 
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with pancreas divisum (dorsal duct not attempted or injected), E RCP for biliary stent 
removal or exchange without anticipated pancreatogram, s ubject with prior biliary 
sphincterotomy now scheduled for repeat biliary therapy without anticipated 
pancreatogram, anticipated inability to follow protocol, or known active cardiovascular or 
cerebrovascular disease.  
 
Randomization and Masking 
Eligible patients underwent randomization at the conclusion of the ERCP, because 
patients without a priori risk factors for pancreatitis could be included in the study on the 
basis of procedure-related factors that developed during the case. Immediately after the 
procedure, if the endoscopist and research coordinator determined that eligibility criteria 
had been satisfied, patients were randomly assigned to receive either two 50mg 
indomethacin suppositories and a placebo suppository (standard-dose group) or three 
50mg indomethacin suppositories (high-dose group). Four hours after the ERCP, 
patients who were assigned to the high-dose group (having already received 150mg) 
received an additional 50mg indomethacin suppository whereas patients in the 
standard-dose group (having already received 100mg) received an additional placebo 
suppository. While the indomethacin and placebo suppositories were not identical, 
suppositories were administered by clinical nursing personnel uninvolved in the post-
procedure care of patients or the adjudication of study outcomes. 
An identical administration regimen in both groups and the exclusion of investigators 
and research coordinators (who were involved in the care of the patient and the 
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assessment of outcomes) from placing the suppositories were intended to ensure that 
study subjects, treating physicians and study coordinators remained blinded to study 
group assignment. The success of study blinding, however, was not formally assessed.  
The randomization schedule was generated centrally at the University of Michigan by an 
investigator uninvolved in the clinical care of any subjects (AKW) using the Stata 12.1 
ralloc command (StataCorp, College Station, TX, USA) and was stratified according to 
study center. There were no additional restrictions to sequence generation. The 
randomization schedule was provided to the investigational drug service (Medical 
University of South Carolina and University of Michigan) or a research coordinator not 
directly involved in the trial (other sites) who then dispensed the assigned suppositories 
according to the randomization schedule upon being informed by the study coordinator 
that a patient had met eligibility criteria. This same personnel was responsible for 
packaging the drug and placebo in opaque envelopes. With this method of allocation, 
assignment to study group was concealed from study participants, treating physicians 
and coordinators without knowledge of the next assignment in the sequence. 
 
Procedures 
All ERCP procedures were performed under general anaesthesia or monitored 
anaesthesia care (deep sedation) according to standards established at each individual 
site. All procedure-related interventions, including method of cannulation, all 
therapeutics and the decision to place a prophylactic pancreatic stent, were left to the 
discretion of the attending endoscopist. Experience of each endoscopist ranged from an 
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average of 200 to 800 ERCP procedures performed on an annual basis. The first dose 
was administered immediately after ERCP while the patient was still in the procedure 
room. The second dose was administered in the recovery area or in a clinic examination 
room (if the patient had been discharged and returned later for the second dose). The 
study protocol did not allow for dose reductions or interruptions. All study patients, 
regardless of randomization arm, received aggressive intravenous fluid administration 
peri- and post-procedure in an attempt to minimize pancreatitis risk, per institutional 
practice, unless contraindications were present (e.g., history of congestive cardiac 
failure, liver disease with ascites).  
The indomethacin suppositories were purchased from one manufacturer: G&W 
Laboratories, Inc. (South Plainfield, NJ). With the exception of the Medical University of 
South Carolina site, which purchased its own indomethacin suppositories from G&W, all 
suppositories were purchased by the Indiana University clinical research team and then 
distributed directly to each participating site by IROKO Pharmaceuticals, LLC 
(Philadelphia, PA). Formal potency testing had previously confirmed that the vendor 
provided indomethacin suppositories that were pharmacodynamically equivalent.5  
 
Most patients were observed in the recovery area after the procedure for 4 hours, at 
which point they received the second study dose of indomethacin or placebo. Patients 
in whom abdominal pain developed during this observation period which was 
unresponsive to oral analgesics were admitted to the hospital (or for current inpatients, 
kept in the hospital). A small fraction of clinically well patients were discharged from the 
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recovery area after approximately 90 minutes and returned at the 4-hour mark to 
receive the second dose.  
Decisions regarding the evaluation and treatment of adverse events after the procedure 
and in-hospital care were left to the discretion of the endoscopist and treating clinicians, 
all of whom were unaware of study group assignment. Among hospitalized patients, 
serum amylase and lipase levels were measured at least once approximately 24 hours 
after the procedure and subsequently at clinical discretion. 
Patients who were discharged after an uneventful ERCP were contacted by telephone 
at 5±2 days to capture delayed occurrence of the primary endpoint. Patients were again 
contacted at 30±5 days to assess for delayed adverse events and to determine the 
severity of post-ERCP pancreatitis, which is defined in part by the length of 
hospitalization for pancreatitis.22 No specific follow-up laboratory monitoring was 
required unless clinical required by a treating physician. Patient demographics, risk 
factors, ERCP procedural elements, and follow-up data were recorded on standardized 
data collection forms by a study coordinator who was unaware of study group 
assignment. Assessment of the primary outcome was centrally reviewed the study 
coordinator and primary investigator at the Indiana University site, both of whom were 
blinded to treatment group allocation.  Patients were free to withdraw from the study at 
any time after signing informed consent, with no criteria for investigator-initiated patient 
withdrawal. Analyses were performed by intent-to-treat principle. Patients were 
considered lost to follow-up for the 5-day or 30-day endpoints if repeated efforts to 
contact them and/or to obtain their medical records were unsuccessful when the trial 





The primary outcome of the study was the development of post-ERCP pancreatitis, 
which was defined according to consensus criteria: new onset (or worsening of 
baseline) pain in the upper abdomen, an elevation in pancreatic enzymes of at least 
three times the upper limit of the normal range approximately 24 hours after the 
procedure, and hospitalization for at least 2 nights.22 The secondary outcome was the 
development of moderate or severe post-ERCP pancreatitis. Moderate post-ERCP 
pancreatitis is defined as that requiring a 4-10 day hospitalization, while severe 
pancreatitis leads to hospitalization >10 days, or any of: intensive care unit stay, 
development of necrosis, pseudocyst, radiologic/surgical intervention, or death. 
Adjudication of outcome was made by the site research nurse, confirmed by the treating 
physician who were both blinded to study group allocation, and then forwarded to the 
central site for confirmation.  
Adverse events were defined as reported previously.22,23 Adverse events that were 
potentially attributable to the study drug were reported to the local institutional review 
board and the DSMB. These reportable adverse events were gastrointestinal bleeding, 






Our prior large-scale randomized trial, which compared 100mg of rectal indomethacin to 
placebo among 602 high-risk patients, employed identical eligibility criteria and a similar 
protocol to this study.5 That trial revealed a rate of post-ERCP pancreatitis of 9.2% (27 
of 295 patients) in the indomethacin group. Thus we estimated that 1036 patients (518 
per study group) would provide a power of at least 80% to detect a 50% reduction in the 
incidence of post-ERCP pancreatitis, from 9.2% in the 100mg group to 4.6% in the 
200mg group, on the basis of Fisher’s exact test, with a two-sided significance level of 
0.05. This absolute reduction in incidence was felt to be clinically relevant and 
substantial enough to change existing clinical practice. 
 
For the analysis of the primary outcome in this superiority trial, we used a two-tailed 
Fisher’s exact test to analyze the difference in the proportion of patients with post-ERCP 
pancreatitis in the two groups, with a final two-sided P value of less than 0.05 indicating 
statistical significance. The secondary outcome, the proportion of patients with 
moderate or severe post-ERCP pancreatitis in each study group, was similarly 
calculated. Both the primary and secondary analyses were conducted by intention-to-
treat. 
When information for the first 400 patients (37.7% of total enrollment) could be 
evaluated, an ad hoc rule was used to trigger a blinded interim analysis by the 
independent DSMB. If greater than 66% of the pancreatitis cases or bleeding cases 
were in a particular group, a formal comparison between groups would be performed 
with the use of a two-sided stopping boundary of 0.005. Similarly, the DSMB 
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recommended a second interim analysis after 600 patients (56.6% of total enrollment) 
were evaluated to ensure the safety of subjects. 
To generate hypotheses regarding patient groups that may particularly benefit from the 
high-dose indomethacin regimen, we performed exploratory subgroup analyses on the 
following pre-specified patient and procedural characteristics: age, sex, race, body 
mass index, suspicion of sphincter of Oddi dysfunction, prior post-ERCP pancreatitis, 
history of recurrent pancreatitis, difficult cannulation, performance of pancreatography, 
pre-cut (access) sphincterotomy, pancreatic sphincterotomy, pancreatic acinarization, 
biliary sphincterotomy, double wire cannulation technique, pancreatic stent placement, 
trainee involvement, cardioprotective aspirin use, inpatient vs. outpatient status, and 
participating medical center. All subgroup analyses were evaluated for interaction 
effects with indomethacin dose by testing for significance of a corresponding interaction 
term in a multiple logistic-regression model.24 Statistical analyses were conducted using 
STATA 14.2 (StataCorp, College Station, TX, USA). The sample size was estimated 
using STATA 12.1 during the design phase of the trial. 
 
All authors had access to the study data and reviewed and approved the final 
manuscript. This trial was registered with Clinicaltrials.gov 
(https://www.clinicaltrials.gov/): NCT01912716).  
Role of the Funding source  
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all 
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From July 9, 2013 through March 22, 2018, a total of 1037 eligible subjects were 
enrolled (Figure 1), all of whom had data available for analysis (see appendix p11). 
Three additional patients were enrolled who did not meet eligibility (inclusion) criteria, 
and one patient had the informed consent signed by her legal authorized representative. 
Data from these four patients were not included in the analyses after discussion with the 
study DSMB. Indications for ERCP included the following (some patients had more than 
one indication): suspected sphincter of Oddi dysfunction or post-sphincterotomy 
stenosis (559 patients), choledocholithiasis (57), abnormal liver function tests (132), 
recurrent acute pancreatitis (381), pancreas divisum (148), papillectomy (68), primary 
sclerosing cholangitis (8), bile leak (5), and a number of less frequent indications. In 
February 2015 and February 2016, interim analyses were performed by the DSMB to 
assess the outcomes of the first 400 and 600 patients, respectively. Both analyses 
failed to meet the predetermined stopping criteria, and recommendations were made to 
continue the study. Ultimately, 515 patients were randomized to receive the standard 
dose of rectal indomethacin (100mg) whereas 522 were randomized to receive the high 
dose (200mg). Every patient in both groups received the immediate post-procedural 
suppositories. Twelve (2.3%) of 515 patients in the standard-dose group and 11 (2.1%) 
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of 522 patients in the high-dose group did not receive the 4-hour post-procedural 
suppository. Thus 11 patients in the high-dose group received only 150mg of 
indomethacin but were analyzed according to the intention-to-treat principle. None of 
these 23 patients who did not receive the second dose chose to do so due to drug-
related toxicity, but most commonly chose to leave the recovery area before the 4-hour 
time period had elapsed.   
 
Follow-up of all patients for the primary endpoint was complete (Figure 1). All 1037 
patients, therefore, were included in the analysis of the primary outcome, with a median 
follow-up of 5 days and interquartile range (IQR) of 1. Nine (0.9%) of 1037 patients were 
lost to follow-up at the 30-day visit and thus could not be fully assessed for delayed 
adverse events. Of these, 3 (0.3%) of the 1037 patients had developed post-ERCP 
pancreatitis and thus could not be included in the analysis of the secondary endpoint 
(severity of post-ERCP pancreatitis), leaving 1034 patients (99.7%) available for 
analysis. The median follow-up for analysis of the secondary outcome and delayed 
adverse events was 30 days with an IQR of 2. Baseline characteristics, including all 
major and minor inclusion criteria, were similar in the two study groups, except that 
patients in the high-dose group had a lower rate of pre-cut sphincterotomy (46/515, 





The primary outcome of post-ERCP pancreatitis occurred in 141 of 1037 patients 
(13.6%). Of these events, 76 of 515 (14.8%) occurred in the standard-dose group and 
65 of 522 (12.5%) occurred in the high-dose group (P = 0.32; RR 1.19, 95%CI 0.87-
1.61; Figure 2). The secondary outcome of moderate or severe post-ERCP pancreatitis 
occurred in 56 patients: 28 (5.4%) of 515 patients in the standard-dose group and 28 
(5.4%) of 522 patients in the high-dose group (P = 1.000) (Figure 2). Four (0.8%) of 515 
patients in the standard-dose group and 2 (0.4%) in the high-dose group experienced 
severe post-ERCP pancreatitis. Of the severe cases, 5 were hospitalized for 10 days or 
longer and 1 in the high-dose group developed a pancreatic fluid collection that required 
drainage. No cases of cardiopulmonary organ failure were observed. One patient did 
develop transient renal failure (described below, Adverse Events) which resolved within 
48 hours. 
 
Exploratory Subgroup Analyses 
With the exception of patients in whom pancreatic acinarization occurred or those with a 
prior history of post-ERCP pancreatitis, all trends observed in the subgroup analysis 
were not significant (P>0.05; Figure 3). In the majority of subgroups, a trend favoring the 
high-dose regimen at a magnitude similar to the overall effect was observed. We 
observed a lower event associated with the high-dose regimen in the subgroups of 
patients who experienced acinarization (RR 0.12, 95% CI 0.016-0.87) or had a history 





There were 19 adverse events that were potentially attributable to the study drug 
(Figure 2). Clinically significant bleeding occurred in 14 of the 1037 patients (1.4%), 
6/515 (1.2%) in the standard-dose group and 8/522 (1.5%) in the high-dose group (P = 
0.79). All 14 patients had received a sphincterotomy, 4 of whom also underwent 
papillectomy. Three of the bleeding events required blood transfusion of 2-4 units of 
packed red cells. All 14 patients underwent repeat upper endoscopic evaluation, with 
hemostatic maneuvers required in 8 patients. One patient who had presented with 
hematochezia within 24 hours of ERCP had a negative follow-up EGD/ERCP, and 
subsequent colonoscopy revealed large hemorrhoids. No patient required angiography 
or surgery for hemostasis. The median length of stay for these 14 patients was 3 days, 
with an IQR of 2. Three cases of acute kidney injury developed, all in the high-dose 
group (3/522, 0.6%). We considered acute kidney injury as the same degree of renal 
insufficiency which would have precluded study entry (serum creatinine > 1.4mg/dl). Of 
the three cases, one presented 20 days post-ERCP with dehydration, and the serum 
creatinine normalized with intravenous fluid resuscitation. Both the DSMB and IRB 
considered this not drug-related. In the second case, the primary in-patient surgical 
team had decreased the intravenous fluids to maintenance rate only 2 hours post-
ERCP, serum creatinine was 1.46 mg/dl the following day, but returned to baseline the 
next day with additional intravenous fluids. This was deemed possibly related to the 
drug by the DSMB, but was not reported to the site IRB. The third case involved a 
patient who developed severe post-ERCP pancreatitis. The creatinine increased to 2.3 
mg/dl by day 2 post-ERCP, but decreased to 1.1 mg/dl by day 3 and remained normal 
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thereafter. This event was also reported to the DSMB but not the site IRB. A non-ST 
elevation myocardial infarction occurred in the standard-dose group 2 days after ERCP. 
A transient ischemic attack occurred in the high-dose group 5 days after ERCP. There 
were no allergic reactions or deaths at the 30-day follow-up. 
 
Discussion: 
Our findings demonstrated that a high-dose treatment regimen (200mg) of rectal 
indomethacin was not more efficacious than the standard 100mg regimen in lowering 
post-ERCP pancreatitis rates in patients at elevated risk for this complication. 
Furthermore, there was no difference in severity of post-ERCP pancreatitis between the 
standard and high-dose groups. While there was a trend towards benefit of the high-
dose group in most subgroups analyzed, this did not reach statistical significance 
except in two situations: patients where acinarization occurred at ERCP or those with a 
prior history of post-ERCP pancreatitis. The explanation for this isolated benefit is purely 
speculative at this point, but additional ad hoc analyses are planned.  
 
Indomethacin shares important pharmacological properties with other nonsteroidal anti-
inflammatory drugs (NSAIDs) and inhibits cyclooxygenase, phospholipase A2 and 
neutrophil-endothelial interactions, all believed to play a major role in the pathogenesis 
of pancreatitis.25-27 While diclofenac undergoes first-pass metabolism with only 50-60% 
of the drug reaching the systemic circulation as intact diclofenac, indomethacin is not 
subject to significant first-pass metabolism. The serum concentration of indomethacin 
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peaks within 30-90 minutes after rectal administration, and bioavailability is 
complete.27,28 This peak concentration is sustained for up to two hours following 
administration and then decreases over four hours.29 In this study, our high-dose 
treatment regimen consisted of a higher indomethacin dose (150mg) immediately post-
ERCP, followed by an additional 50mg dose four hours later. When designing the study 
protocol, we had assumed that a higher initial dose might lead to higher therapeutic 
drug levels, and a second dose might lead to a more sustained effect. It remains 
possible that the entire 200mg dose given immediately post-ERCP, earlier in the 
cascade of events which occur in pancreatitis (rather than the 150mg dose followed by 
the four-hour 50mg dose), may have led to a more beneficial effect than that observed 
here. Alternatively, it has been suggested that administration of an NSAID at the 
beginning of the ERCP or during cannulation rather than at the end of the procedure 
may further reduce pancreatitis rates,8,9 although this point remains controversial and 
additional randomized trials specifically addressing timing of administration would be of 
interest.11-14 Pharmacokinetic studies to determine the optimal regimen and inform 
future randomized trials are necessary.  
 
The rate of post-ERCP pancreatitis observed in both the standard dose (76/515, 14.8%) 
and high-dose (65/522, 12.5%) groups exceeded that observed in our prior randomized 
trial of rectal indomethacin that employed nearly identical eligibility criteria.5 The 
EPISOD trial,30 which changed the way in which patients formerly suspected to have 
Type 3 sphincter of Oddi dysfunction are managed, was published ten months after our 
current study was begun, prompting a protocol change excluding these patients from 
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study entry. However, the interpretation of post-ERCP pain and the decision to 
hospitalize a patient after the procedure, which are components of the definition of post-
ERCP pancreatitis, are subjective and vary according to practice styles and institutional 
policies. Indeed, practitioners with a lower threshold to hospitalize patients after ERCP 
may observe a higher rate of post-procedure pancreatitis, and vice versa. Thus, 
between-study and between-center comparisons of post-ERCP pancreatitis rates must 
be interpreted with caution as they may reflect a different cohort of centers in the study 
or secular temporal changes in practice patterns. 
 
More than 75% of patients (793/1037) in this clinical trial received a pancreatic duct 
stent. Of these, 88% (700/793) received a temporary, protective pancreatic duct stent 
on the basis of their increased risk of post-ERCP pancreatitis, with no difference in 
incidence of stent placement between the standard indomethacin dose and high-dose 
groups. Certain patients, however, did not receive temporary stents, either because the 
endoscopist did not believe this was indicated,31 or less frequently, because placement 
was not technically feasible (ansa loop ductal configuration prohibiting wire passage). 
Regardless of whether a protective stent was placed, there was no difference observed 
in pancreatitis rates between the standard indomethacin dose and high-dose regimens. 
Nearly 12% of patients (93/793) who received a pancreatic duct stent had a therapeutic 
stent placed, typically for management of chronic pancreatitis. Similarly, there was no 
difference in pancreatitis rates between the two indomethacin regimens, regardless of 
whether a therapeutic stent was placed. The results of our study are similar to a recent 
study from Taiwan.32 This single center, randomized trial of 162 patients also failed to 
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demonstrate a benefit of double dose rectal indomethacin (200mg) compared to the 
standard single dose (4.8% vs 9.5%, P=0.24). However, these two studies clearly 
evaluated different patient populations. The Taiwanese study recruited consecutive 
patients undergoing ERCP for all indications, the majority of which (144/162) were 
performed for choledocholithiasis. Furthermore, when considering procedural 
characteristics as well, only 42/162 patients were considered to be at high-risk for post-
ERCP pancreatitis, in contrast to our study.  
There are a number of limitations in this study. While patients were recruited from six 
busy US academic centers, 760 of 1037 patients (73.3%) were recruited from one site, 
potentially limiting generalizability. We acknowledge that patients with chronic 
pancreatitis are typically considered to be at reduced risk of ERCP-induced pancreatitis. 
However, these patients qualified for study entry due to the presence of additional high-
risk features.21 Furthermore, patients with calcific pancreatitis, a protective factor 
against post-ERCP pancreatitis, were excluded. This study was not designed a priori to 
determine the benefit of pancreatic duct stent placement vs. indomethacin alone vs. 
combination stent+indomethacin, as is currently being investigated elsewhere.31 
Additionally, aggressive intravenous fluid administration, particularly lactated ringers, 
has recently been shown to have a protective effect against post-ERCP pancreatitis.33,34 
While this recommendation was followed at each site according to institutional and 
physician practice, a set protocol with type and volume of fluid was not followed or 
systematically tracked across all sites, as this study began patient recruitment in 2013. 
Furthermore, established consensus criteria22 for the definition of post-ERCP 
pancreatitis were used in this study. These consensus criteria have been most 
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commonly used in landmark trials on post-ERCP prevention, epidemiological studies 
and in ERCP guidelines.35 However, duration of hospitalization is a key component of 
these criteria, which may be confounded by patient pain tolerance and physician 
practice, among other factors. The revised Atlanta classification of acute pancreatitis 
consensus definitions stratify pancreatitis severity based on the presence of local and 
systemic adverse events, including duration of organ failure, rather than duration of 
hospitalization.36 Although not specific for post-ERCP pancreatitis, the revised Atlanta 
classification may provide an alternative for assessing the severity of this 
complication.35 
 
NSAIDs are an attractive option in the prevention of post-ERCP pancreatitis, as they are 
easily administered, relatively inexpensive and have a favorable risk profile when given 
as a single dose. An initial concern with the current trial was the potential for increased 
adverse events with the 200mg dose. However, the observed risk of adverse events 
that were potentially attributable to indomethacin was similar in the standard and high-
dose regimens. Specifically, there was no significant difference between the groups in 
the frequency or severity of bleeding events, consistent with prior reports that NSAIDs 
(in standard doses) do not increase the rate of post-sphincterotomy bleeding.3,37 As with 
our previous randomized trial,5 patients with contraindications to NSAIDs were excluded 
from study participation.  
 
In summary, dose escalation to 200mg of rectal indomethacin does not appear to confer 
an advantage over the standard 100mg regimen. Post-ERCP pancreatitis rates continue 
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to remain high in high-risk patients despite rectal indomethacin. Additional interventions 
are necessary to further reduce the risk of post-ERCP pancreatitis.      
 
Research in context 
Evidence before this study 
Pancreatitis is the most common and most-feared complication of ERCP. Rectal non-
steroidal anti-inflammatory drugs – either indomethacin or diclofenac at a dose of 
100mg in the peri-procedural period – have been adopted into widespread clinical use 
in an attempt to minimize the likelihood of this complication. A systematic literature 
review using the PubMed, Ovid and Cochrane Library electronic databases as well as 
ClinicalTrials.gov to facilitate identification of ongoing trials was performed, with a start 
date of January 1, 1990 and end date of June 30, 2019. The electronic search was 
performed using the search terms "post-ERCP complications”, “post-ERCP pancreatitis 
prevention”, NSAIDs and pancreatitis” AND "indomethacin and pancreatitis prevention", 
without limitation to type of study (eg. randomized controlled trial) or English language. 
The pooled estimate from several meta-analyses demonstrates an approximately 50% 
risk reduction in high-risk patients. The rate of post-ERCP pancreatitis, however, 
remains at or above 10% in high-risk cases despite this intervention. The optimal dose 
of this phamacoprevention is unknown. 
Added value of this study 
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Rectal NSAIDs have been shown to reduce the incidence of post-ERCP pancreatitis in 
high-risk patients. This primary objective of this study was to determine whether a more 
aggressive, high-dose indomethacin regimen (200mg) would further lower the risk of 
this complication. While this study demonstrates that the high-dose regimen does not 
appear to offer any advantage over the standard dose (100mg), the importance of the 
study is undeniable. NSAIDs have been the sole effective pharmacopreventive strategy 
identified to date to definitively reduce post-ERCP pancreatitis rates, and studies to 
define the optimal dose and timing of administration are needed to refine this 
intervention. This “negative” study will help guide the design of future trials aimed at 
reducing the incidence of this complication. 
Implications of all the available evidence 
Published guidelines from the American College of Gastroenterology and the American 
and European Societies for Gastrointestinal Endoscopy support the administration of 
rectal NSAIDs for the prevention of post-ERCP pancreatitis in high-risk patients. This 
study failed to demonstrate a clear benefit of a high-dose regimen of rectal 
indomethacin, and current practice patterns should continue unchanged. However, 
further research needs to consider the pharmacokinetics of NSAIDs to determine the 
optimal timing of their administration in prevention of post-ERCP pancreatitis. It remains 
possible that administration of a high-dose prior to the procedure, perhaps given as a 
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Figure 1. Enrollment and Outcomes 
Figure 2. Incidence of (A): Post-ERCP Pancreatitis and (B): Adverse Events, in the two 
treatment groups 




Table 1: Baseline Characteristics 
Characteristic  100 mg regimen 
(N=515) 
200 mg regimen 
(N=522) 
Age – years (SD) 49.3 (15.2) 50.4 (15) 
Female sex – no. (%)  392 (76.1) 421(80.7) 
Body mass index (SD) 28.6 (7.03) 29.2 (7.63) 
Obese (BMI ≥ 30) – no (%) 193 (37.5) 198 (37.9) 
Clinical suspicion of sphincter of Oddi 
dysfunction — no. (%) 
319 (61.8) 331 (63.4) 
History of post-ERCP pancreatitis — 
no. (%) 
77 (15) 100 (19.2) 
History of recurrent pancreatitis — no. 
(%) 
202 (39.2) 210 (40.2) 
Difficult cannulation (>8 attempts) — 
no. (%) 
148 (28.7) 146 (28) 
Precut sphincterotomy — no. (%) 71 (13.8) 46 (8.8) 
Double-wire cannulation technique – 
no. (%) 
18 (3.5) 18 (3.4) 
Pancreatography 
      Patients — no. (%) 446 (87) 433 (83) 
      Mean no. of injections of the     
      pancreatic duct (SD) 
2.12 (1.63) 1.96 (1.66) 
Pancreatic sphincterotomy — no. (%) 245 (47.6) 231 (44.3) 
Placement of pancreatic stent — no. 
(%) 
 400 (77.7) 393 (75.3) 
Papillectomy — no. (%) 30 (5.8) 32 (6.1) 
Biliary sphincterotomy — no. (%) 302 (58.8) 290 (55.6) 
Trainee involvement in ERCP — no. 
(%) 








1401 Patients provided informed consent  
Excluded  (n= 364) 
♦   Did not meet inclusion criteria (n=256) 
♦   Did not undergo ERCP (n= 41) 
♦   Met exclusion criteria (n=35) 
♦   Case too late for second dose (n=22) 
♦   Other reasons (n=10) 
         - 5 withdrew informed consent 
         - 3 unable to verify creatinine level  
         - 1 unable to provide informed consent 
          -1 unable to follow protocol 
         
Included in primary analysis (n=515) 
Included in secondary analysis (n=513) 
Lost to follow-up for primary endpoint (n=0) 
Lost to follow-up for secondary endpoint (n=2) 
Lost to follow-up for adverse events (n=3) 
 
Allocated to 100 mg regimen (n=515) 
♦ Received first dose (100 mg) (n=515) 
♦ Received second dose (placebo) (n=503) 
 
Lost to follow-up for primary endpoint (n=0) 
Lost to follow-up for secondary endpoint (n=1) 
Lost to follow-up for adverse events (n=6) 
 
 
Allocated to 200 mg regimen (n=522) 
♦ Received first dose (150 mg) (n=522) 
♦ Received second dose (50 mg) (n=511) 
 
Included in primary analysis (n=522) 
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